Drug Safety

, Volume 24, Issue 10, pp 781–792

Postdischarge Adverse Drug Reactions in Primary Care Originating from Hospital Care in France

A Nationwide Prospective Study
  • Laurent Letrilliart
  • Thomas Hanslik
  • Michel Biour
  • Jean-Paul Fagot
  • Marguerite Guiguet
  • Antoine Flahault
Original Research Article

DOI: 10.2165/00002018-200124100-00006

Cite this article as:
Letrilliart, L., Hanslik, T., Biour, M. et al. Drug-Safety (2001) 24: 781. doi:10.2165/00002018-200124100-00006

Abstract

Objective: To describe and estimate the incidence and preventability of postdischarge adverse drug reactions (ADRs) detected in primary care in France.

Design: Prospective study of patients referred to hospital by participating general practitioners (GPs). These GPs reported all cases of an adverse reaction to a drug instituted in hospital among patients who consulted them within 30 days of discharge.

Setting: 305 general practices from all French regions.

Patients: 7540 patients referred by GPs to private or public hospitals.

Main outcome measures: The incidence for postdischarge ADRs in primary care, and their preventability.

Results: 30 cases of postdischarge ADR were detected in 29 re-consulting patients, yielding a minimal incidence for France of 0.4 per 100 admissions (95% confidence interval 0.3 to 0.6). The ADRs were assessed as serious in 60% of cases. The main drug classes implicated were cardiovascular drugs (8 ADRs), oral anticoagulants (6), psychoactive drugs (4), antidiabetics (3), and opioid analgesics (3). Patients experiencing a postdischarge ADR were older than patients not experiencing one (median age: 77 vs 68 years; p = 0.004). Detected ADRs were considered preventable in 59% of cases.

Conclusions: Physicians and patients should be aware of the possible occurrence of postdischarge ADRs. Patient information in hospital, close postdischarge follow-up of patients at risk, and appropriate transmission of information between hospital physicians and GPs can help to prevent them.

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  • Laurent Letrilliart
    • 1
  • Thomas Hanslik
    • 2
  • Michel Biour
    • 3
  • Jean-Paul Fagot
    • 1
  • Marguerite Guiguet
    • 1
  • Antoine Flahault
    • 1
  1. 1.INSERM Unit 444, WHO Collaborating Centre for Electronic Disease SurveillanceNational Institute for Health and Medical Research (INSERM), Université Paris 6ParisFrance
  2. 2.Department of Internal MedicineAmbroise-Paré Hospital, Boulogne-Billancourt, and Université Paris 5ParisFrance
  3. 3.Regional Centre for Pharmacovigilance and Drug InformationSaint-Antoine HospitalParisFrance